Bristol Myers Squibb announced that the European Commission has granted full Marketing Authorization for Reblozyl, a first-in-class therapeutic option, for treatment in adult patients of anemia associated with non-transfusion-dependent beta thalassemia. Reblozyl is currently approved in the European Union, United States and Canada to address anemia associated with transfusion-dependent beta thalassemia and transfusion-dependent lower-risk myelodysplastic syndromes. The centralized Marketing Authorization approves use of Reblozyl in all EU member states, as well as Norway, Iceland and Liechtenstein.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Bristol-Myers and Johnson & Johnson launch Phase 3 trial of milvexian
- Bristol-Myers: FDA accepts sBLA for Opdivo
- Bristol Myers Squibb put volume heavy and directionally bearish
- Bristol-Myers announces three-year results from Phase 3 CheckMate-274 trial
- Bristol-Myers’ Opdivo and Exelixis’ Cabometyx show durable survival in carcinoma